Boutroy M J, Bianchetti G, Dubruc C, Vert P, Morselli P L
Eur J Clin Pharmacol. 1986;30(6):737-9. doi: 10.1007/BF00608227.
The concentrations of acebutolol and of its main active metabolite diacetolol in milk and plasma were studied in 7 hypertensive mothers treated with acebutolol, a cardioselective beta-adrenoceptor blocking agent. Clinical monitoring on their newborn babies was also done, as well as measurement of plasma level of the drug in them. The ratio between milk and plasma concentrations ranged from 1.9 to 9.2 for acebutolol and from 2.3 to 24.7 for diacetolol, and in any given milk sample, the diacetolol concentration was always higher than that of acebutolol. In a newborn infant, plasma concentrations of the two transplacentally acquired substances was raised when breast feeding started and remained high. Clinical signs of pharmacological beta-blockade were observed. Evaluation of the iatrogenic risk shows that pharmacologically active amounts of acebutolol might be received by a neonate if the daily maternal dosage exceeds 400 mg/day and/or renal function in the mother is impaired.
对7名接受心脏选择性β-肾上腺素受体阻滞剂醋丁洛尔治疗的高血压母亲，研究了其乳汁和血浆中醋丁洛尔及其主要活性代谢物双醋丁洛尔的浓度。同时对她们的新生儿进行了临床监测，并测定了新生儿血浆中的药物水平。醋丁洛尔的乳汁与血浆浓度之比为1.9至9.2，双醋丁洛尔为2.3至24.7，在任何给定的乳汁样本中，双醋丁洛尔的浓度总是高于醋丁洛尔。在一名新生儿中，开始母乳喂养时，这两种经胎盘获得的物质的血浆浓度升高并维持在较高水平。观察到了药理学β受体阻滞的临床体征。对医源性风险的评估表明，如果母亲每日剂量超过400毫克/天和/或母亲的肾功能受损，新生儿可能会摄入药理活性量的醋丁洛尔。
